Diagnosis and Management of Pediatric Hypereosinophilic Syndrome

Chen E Rosenberg; Patricia C Fulkerson; Kelli W Williams

doi:10.1016/j.jaip.2022.02.007

Diagnosis and Management of Pediatric Hypereosinophilic Syndrome

J Allergy Clin Immunol Pract. 2022 May;10(5):1131-1138. doi: 10.1016/j.jaip.2022.02.007. Epub 2022 Feb 15.

Authors

Chen E Rosenberg¹, Patricia C Fulkerson², Kelli W Williams³

Affiliations

¹ Division of Pediatric Allergy and Immunology, Massachusetts General Hospital, Boston, Mass.
² Division of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
³ Division of Pediatric Pulmonology, Allergy, and Immunology, Department of Pediatrics, Medical University of South Carolina, Charleston, SC. Electronic address: williamske@musc.edu.

PMID: 35181546
DOI: 10.1016/j.jaip.2022.02.007

Abstract

Hypereosinophilic syndrome (HES) is a diverse group of disorders characterized by peripheral blood eosinophilia of 1.5 × 10⁹/L (1,500/μL) or greater with evidence of end-organ damage attributable to eosinophilia and no other cause of the end-organ damage. The HES is rare, especially in children. This review aims to provide best practices in diagnosis and treatment of HES in children, including how to differentiate between primary and secondary causes of hypereosinophilia; how to distinguish the differences in clinical presentation, treatment, and prognosis of HES in children and adults; and how to identify key steps in the evaluation and management of HES in children.

Keywords: Children; Elevated eosinophils; Hypereosinophilia; Hypereosinophilic syndrome; Pediatric.

Publication types

Review

MeSH terms

Adult
Child
Humans
Hypereosinophilic Syndrome* / diagnosis
Hypereosinophilic Syndrome* / therapy
Prognosis
World Health Organization